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Abstract
AIM: To evaluate and compare the effect of combined
transarterial chemoembolization (TACE) and arterial
administration of Bletilla striata (a Chinese traditional
medicine against liver tumor) versus TACE alone for the
treatment of hepatocellular carcinoma (HCC) in ACI rats.
METHODS: Subcapsular implantation of a solid Morris
hepatoma 3 924A (2 mm
3) in the liver was carried out in 30
male ACI rats. Tumor volume (V1) was measured by magnetic
resonance imaging (MRI) on day 13 after implantation. The
following different agents of interventional treatment were
injected after retrograde catheterization via gastroduodenal
artery (on day 14), namely, (A) TACE (0.1 mg mitomycin +
0.1 ml Lipiodol) + Bletilla striata (1.0 mg) (n=10); (B) TACE
+ Bletilla striata (1.0 mg) + ligation of hepatic artery (n=10),
(C) TACE alone (control group, n=10). Tumor volume (V2)
was assessed by MRI (on day 13 after treatment) and the
tumor growth ratio (V2/V1) was calculated.
RESULTS: The mean tumor volume before (V1) and after
(V2) treatment was 0.0355 cm
3 and 0.2248 cm
3 in group A,
0.0374 cm
3 and 0.0573 cm
3 in group B, 0.0380 cm
3 and
0.3674 cm
3 in group C, respectively. The mean ratio (V2/V1)
was 6.2791 in group A, 1.5324 in group B and 9.1382 in
group C. Compared with the control group (group C), group
B showed significant inhibition of tumor growth (P<0.01),
while group A did not (P>0.05). None of the animals died
during implantation or in the postoperative period.
CONCLUSION: Combination  of  TACE  and  arterial
administration of Bletilla striata plus ligation of hepatic
artery is more effective than TACE alone in the treatment
of HCC in rats.
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INTRODUCTION
HCC is a highly malignant tumor with a very high morbidity
and mortality rate worldwide, carrying a poor prognosis due to
its rapid infiltrating growth and complicating liver cirrhosis
[1,2].
      Surgical resection, liver transplantation and cryosurgery
are regarded as potentially curative treatment for HCC
[3-5], but
most patients are not suitable candidates
[6-9]. Thus, the local
interventional therapy of liver tumor has been rapidly evolving
currently, which includes transarterial chemoembolization
(TACE), percutaneous ethanol injection (PEI), radiofrequency
ablation (RFA), laser-induced thermotherapy (LITT) and
microwave coagulation therapy (MCT)
[10-19]. TACE is one of
the most common forms of interventional therapies and seems
most effective against encapsulated small HCCs without
extracapsular invasion, whereas in large HCCs, viable residual
tumor cells remain and the tumor frequently recurs
[20-22].
Moreover, in patients with large lesions, multiple TACE
sessions are necessary to control tumor growth but may increase
the risk of worsening hepatic function through damage to
noncancerous liver parenchyma
[8,21,23].
       In the past years, locoregional Chinese medicinal therapy
for treating unresectable HCC has been reported with
encouraging results, especially for inhibiting arterial collaterals
of liver tumor and recurrence of HCC
[24,25]. Such an adjuvant
treatment in conjunction with TACE has the potential to
enhance the therapeutic effect of TACE alone in experimental
and clinical studies. However, no experimental study to assess
the value and efficacy of this combined therapy in an animal
model of HCC has been performed.
      The current prospective randomized study was designed
to compare the effect of combined TACE and arterial
administration of Bletilla striata (a Chinese traditional medicine
against liver tumor) versus TACE alone for the treatment of
HCC in ACI rats.
MATERIALS AND METHODS
Tumor
The hepatoma cell line (Morris hepatoma 3924A), a rapidly
growing, poorly differentiated hepatocellular carcinoma
[26], was
used in ACI rats in this study. The hepatoma specimens were
obtained from the German Cancer Research Center (DKFZ;
Heidelberg, Germany).
Animal
Thirty inbred male ACI-rats (Harlan Winkelmann; Borchen,
Germany) weighing 220-260 g were used. The animals were
kept under conventional conditions with a temperature of
22±2  , a relative humidity of 55±10 %, a dark-light rhythmof 12 hr, and had free access to laboratory chow and tap water.
All of the experiments on animals were approved by the
German government.
Agents
The original material of Bletilla striata microspheres is the
stem tubers of Bletilla striata. Bletilla striata microspheres
were kindly provided by Tongji Medical College (Wuhan,
China). A dose of 1.0 mg Bletilla striata microspheres (50 µm)
was suspended in 0.5 ml 0.9 % NaCl for 10 minutes before
administration.
Anesthesia
The animals were anesthetized with intraperitoneal injection
of ketamine hydrochloride (Ketanest, Parke-Davis, Germany;
100 mg/kg), Xylazinhydrochloride (Rompun, Bayer, Germany;
15 mg/kg) and atropine sulfate (Atropinsulfat Braun, Braun,
Germany; 0.1 mg/kg) in all interventional and imaging procedures.
Tumor implantation (on day 1)
The technique for tumor implantation was basically similar to
that described by Yang et al
[26] with minor modifications
[27-29].
The Morris hepatoma 3924A tumor tissue, recovered from the
passaged animals 2 weeks after subcutaneous implantation
(corresponding to 5×10
6 tumor cells), was cut into small cubes
about 2 mm
3.
      A small subcapsular incision on the left lateral lobe of the
liver was made in the recipient ACI-rats under anesthesia. The
tumor fragment was gently placed into the pocket with a small
cotton swab on the liver surface and the abdominal wall was
then closed.
Interventional therapy (on day 14)
For interventional studies a second laparotomy was performed.
By using a binocular operative microscope (M651, Leica;
Wetzler, Germany), a PE-10 polyethylene microcatheter (inner
diameter 0.28 mm, outer diameter 0.61 mm; Wenzel; Heidelberg,
Germany) was retrogradely inserted into the gastroduodenal
artery. Different agents were then injected (20 minutes a
duration time) through the microcatheter via hepatic artery
using sandwich technique. Administration was as follows:
Group A (n=10): Mitomycin (0.1 mg) + Lipiodol (0.1 ml) +
     Bletilla striata (1.0 mg)
Group B (n=10): Mitomycin (0.1 mg) + Lipiodol (0.1 ml) + Bletilla
   striata (1.0 mg)+ligation of A. hepatica propria
Group C (n=10): Mitomycin (0.1 mg) + Lipiodol (0.1 ml)
     (control group).
MR imaging and analysis (on day 13 and 27)
A 1.5 Tesla Sonata (Siemens; Erlangen, Germany) supplemented
by a wrist coil (Small field of view) was used for MRI before
and after therapy (on day 13 and 27). T1-weighted (SE: TR/
TE, 460/15 ms) and T2-weighted (TSE: TR/TE, 3170/99 ms)
transverse images with a section thickness of 2 mm and
184×256 matrix were acquired. There was no gap between
sections and no contrast medium was administered. The tumor
volume was determined and evaluated in T2-weighted image
according to the formula
[30]:
       Largest diameter (mm)×





      The mean tumor growth ratio (V2/V1) was analyzed by
using t test for comparing the effect of each therapeutic group
with control group respectively. A P-value less than 0.05 was
considered to indicate a significant difference.
RESULTS
The rate of tumor implantation reached 100 % in all the rats
receiving tumor implantation with Morris hepatoma 3924A.
None of the animals died during implantation or interventional
therapy. A total of 30 individual HCC tumors were seen with
unenhanced MR imaging in the livers of 30 rats (100 %) before
treatment. The tumors showed homogeneously hypointense
on the T1-weighted images and hyperintense on the T2-
weighted  images.  T2-weighted  sequences  provided
significantly higher tumor-liver contrast than T1-weighted
sequences, and improved the detectability of intrahepatic
metastasis. Intrahepatic metastasis occurred in two of 10 rats
(20 %) in group C.
      The mean tumor volume before (V1) and after (V2) therapy
was 0.0355 cm
3 and 0.2248 cm
3 in group A, 0.0374 cm
3 and
0.0573 cm
3 in group B, 0.0380 cm
3 and 0.3674 cm
3 in group
C, respectively. The mean ratio of V2/V1 was 6.2791 in group
A, 1.5324 in group B and 9.1382 in group C. Compared with
the control group (group C, TACE alone), group B (TACE +
Bletilla striata + ligation of hepatic artery) showed significant
inhibition of tumor growth (P<0.01), while group A (TACE +
Bletilla striata) did not (P>0.05).
       The tumor volume ratio (V2/V1) in different groups (n=30)
is shown in Table 1.
Table 1  Tumor volume rate (V2/V1) in different groups (n=30)
Rat             Group A             Group B             Group C
No.   (BS)             (BS+Lig.)             (control)
  1 6.4810 0.8556   5.6284
  2 5.7038 1.4565   9.5091
  3 6.2490 1.6469 10.5063
  4 7.8920 1.3920   7.7416
  5 7.8023 1.6577   8.6378
  6 7.4781 1.6911   8.2029
  7 5.5685 0.9025   8.3670
  8 6.8346 1.9530   8.5399*
  9 5.5800 1.9636 11.5310
10 3.2015 1.8054 12.7182*
BS: Bletilla striata. Lig.: Ligation of hepatic artery; *: tumor with
intrahepatic metastasis.
      In group B (TACE + Bletilla striata + ligation), relative
small tumors with the size of  0.52×0.37 mm
2 and 0.44×0.38
mm
2 in diameter were shown in two treated rats, respectively,
indicating a minimal response but no tumor growth after
therapy compared with that before therapy (Figure 1).
       In group C (control group), the tumor volume was generally
markedly increased in treated rats compared to untreated. Two
rats appeared to be accompanied with intrahepatic metastasis
(Figure 2).
DISCUSSION
Since TACE was introduced as a palliative treatment in
patients with unresectable HCC, it has become one of the most
common forms of interventional therapies
[11,31]. TACE with
iodized oil has been shown to result in regression of HCC and
reduction of systemic toxicity, thus improving the therapeutic
effects
[21,32,33]. However, prolongation of the overall survival of
patients remains questionable
[34]. TACE might ablate a significant
portion of the tumor but had a high rate of recurrence
[35]. In
patients with focal HCC, TACE was well tolerated and
provided a survival benefit. However, no apparent benefit of
it has been found for patients with diffuse HCC
[36,37]. TACE
using various embolizers has been well documented to include
Qian J et al. Combined interventional therapies of HCC          2677Figure 1  A: Images in a ACI rat with a solid HCC in group B. (a) Pretherapy did not enhance T1-weighted MR imaging with SE
sequence (460/15). It shows a small hypointense tumor (arrow) in the left lateral lobe of liver; B: Pretherapeutic unenhanced T2-
weighted MR imaging with TSE sequence (3170/99). The hyperintense lesion with a size of 0.44×0.40 mm
2 (arrow) is well discern-
ible from the surrounding liver tissue. C: Images in a ACI rat with a solid HCC in group B. (a) Posttherapy did not enhance T1-
weighted MR imaging with SE sequence (460/15). It shows a small hypointense tumor (arrow) in the left lateral lobe of liver. D:
Unenhanced T2-weighted MR imaging with TSE sequence (3170/99) after therapy. It shows the inhomogeneous hyperintense
lesion with a size of 0.44×0.38 mm
2 (arrow) and demonstrates that there is no difference between the tumor volume before and
after therapy.
Figure 2  A: Images in a ACI rat with a solid HCC in group C. (a) Pretherapy did not enhance T1-weighted MR imaging with SE
sequence (460/15). It shows a small hypointense tumor (arrow) in the left lateral lobe of liver. B: Unenhanced T2-weighted MR
imaging with TSE sequence (3170/99) after therapy. The hyperintense lesion with a size of 0.49×0.46 mm
2 (arrow) is well discern-
ible from the surrounding liver tissues. C: Images in a ACI rat with a solid HCC in group C. (a) Posttherapy did not enhance T1-
weighted MR imaging with SE sequence (460/15). It shows a large hypointense tumor (arrow) in the left lateral lobe of liver. The
lesion is surrounded by an iregular hypointense area. D: Unenhanced T2-weighted MR imaging with TSE sequence (3170/99)
after therapy. The tumor with a size of 0.96×0.96 mm
2 had a rapid growth compared with that before therapy. It also shows the
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with thrombosed main portal veins. Its therapeutic effect was
also doubtful when the tumor was infiltrative in nature or
hypovascular, too large or too small
[38,39]. The rapid development
of arterial collaterals after these treatments might reduce this
therapeutic effect and thus, inhibition of the development of
arterial collaterals might be important in enhancing the
therapeutic efficacy of these treatments
[40]. In addition, in
patients with large lesions, multiple TACE sessions were
necessary to control tumor growth but might increase the risk
of worsening hepatic function through damage to noncancerous
liver parenchyma
[23]. Moreover, the types and doses of embolic
agents have been extremely variable in several reported studies.
The major problem with embolic agents were twofold
[41]. First,
they could often completely obstruct the hepatic artery, leading
to difficulties in administration of subsequent courses of hepatic
artery chemotherapy. With a relative short half-life of embolic
agents, the effectiveness of TACE was not significantly
improved. Second, it was easy to aggravate the liver cirrhosis
and lead to hepatic failure after repeated TACE. The optimal
treatment modality of TACE is still unknown
[42].
      Today, it is well known that improvement of the overall
therapeutic effect of liver malignancies depends on the
combined therapies. In the past years, locoregional Chinese
medicinal therapy has gained wide acceptance as a safe,
palliative and effective treatment even in patients with large
HCC and liver cirrhosis in China. Bletilla striata (BS) is a
common Chinese traditional medicinal herb and is usually used
as an embolic material in TACE for HCC. Its compositions
are mucilage, starch, and a little volatile oil. In a previous study,
Zheng et al
[24] used BS to embolize the hepatic artery in order
to induce ischemic necrosis and shrinkage of tumor. It mainly
blocked the trunk of the blood-supplying artery of tumor with
a “vascular cast-like appearance”. The embolization was
extensive and lasted longer, hence a better therapeutic effect
[24].
The mechanisms of embolization by BS are attributable to the
following factors: non-absorbent property, total mechanical
obstruction, no influence on coagulative and anticoagulative
systems and secondary obstruction due to injury of the wall of
blood vessels
[43, 44]. Zheng et al
[25] have confirmed that BS has
an adherent function and can expand slowly in blood flow,
leading to mechanical blockade of vessels. It was also
hypothesized that BS could slowly diffuse into the liver
parenchyma around the tumor as a colloidal form, leading to
prolonged anticancer effect and inhibition of collateralisation
and metastasis of tumor
[25]. Compared with gelfoam embolus,
BS had the following characteristics. It could produce extensive
and permanent vascular embolization, while it could not be
absorbed by body tissue. After embolization, tumor necrosis
and shrinkage were significant with less collateral circulation
that formed later. The mucilage component of BS is a wide-
spectrum anticancer element that might inhibit tumor
occurrence and development
[45]. The 1, 2 and 3 year survival
rates were 44.9 %, 33.6 % and 33.6 % in BS group while the
rates were 48.9 %, 31.1 % and 16.0 % in gelfoam group,
suggesting that BS is superior to gelfoam as an embolic agent,
and transarterial administration of BS might provide a
beneficial therapeutic modality for HCC
[45]. In our experimental
study, the best therapeutic effect was the combined therapy of
BS+TACE+ligation of hepatic artery. There was almost no
significant difference between the tumor volume before and
after therapy (Figure 1). No intrahepatic metastasis was
observed in this group. This approach of central- and peripheral
chemoembolization is able to increase the inhibition of tumor
growth more completely, resulting in local control of tumor
growth in rats and has a promising prospect for treating patients
with HCC in the future.
      In summary, by combining TACE and arterial administration
of Bletilla striata plus ligation of hepatic artery for treating
HCC in ACI rats, an encouraging result can be obtained
compared with TACE alone. However, the detailed therapeutic
mechanisms, therapeutic indications, optimal strategy for the
use, monitoring, and validation of these combined therapies
remain unclear and more randomized experimental and clinical
studies are required.
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